"Product Profiles: Stroke Prevention in Atrial Fibrillation - Uptake Slower Than Expected for the First Warfarin Alternatives, the Novel Oral Anticoagulants" - New Market Report
The difficulties with using the standard therapy, warfarin, in this indication have led to the development of the novel oral anticoagulants. Uptake of the two marketed novel therapies, Pradaxa and Xarelto, has been slower than expected. However, the pipeline drug Eliquis has the potential to expand oral anticoagulant usage beyond its traditional patient population.
View full press release